# 2025-03060: DEA Eyes Importing GHB: Date-Rape Drug Gets Pharma Pass?

2025-03060, Importer of Controlled Substances Application: Sharp Clinical Services, LLC, is a Federal Register notice from Justice Department, Drug Enforcement Administration published 2025-02-26, effective Registered bulk manufacturers of the affected basic class(es) and applicants may submit comments or file a request for a hearing on or before March 28, 2025.; PRIA reads it as touching household money (as of 2026-09-25).

- Canonical: https://policyrisk.com/federal-register/2025-03060
- As of: 2026-09-25
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2025-03060
- Title: Importer of Controlled Substances Application: Sharp Clinical Services, LLC
- Type: Notice
- Agencies: Justice Department; Drug Enforcement Administration
- Citation: 90 FR 10730
- Published: 2025-02-26
- Effective: Registered bulk manufacturers of the affected basic class(es) and applicants may submit comments or file a request for a hearing on or before March 28, 2025.
- Comments close: not stated
- Significant: no
- Touches household money: yes
- Regulation identifier numbers: none
- Last updated: 2026-09-25

## In one line

DEA Eyes Importing GHB: Date-Rape Drug Gets Pharma Pass?

## Summary

Sharp Clinical Services, LLC wants to become an official importer of certain controlled substances, like Gamma Hydroxybutyric Acid. If you’re a registered manufacturer or interested party, you have until March 28, 2025, to share your thoughts or ask for a hearing. This move could impact companies dealing with these drugs and the government’s oversight of imports.

## Abstract

Sharp Clinical Services, LLC has applied to be registered as an importer of basic class(es) of controlled substance(s). Refer to Supplementary Information listed below for further drug information.

## Effects PRIA read

- Application to Import Four Schedule I Drugs: benefit, medium. Sharp Clinical Services, LLC applied on January 7, 2025 to be registered to import four Schedule I substances: Gamma Hydroxybutyric Acid (GHB), 3,4-methylenedioxymethamphetamine (MDMA), 5‑Methoxy‑N‑N‑dimethyltryptamine (5‑MeO‑DMT), and psilocybin. The company says it plans to import these substance…
- March 28, 2025 Comment and Hearing Deadline: benefit, low. Registered bulk manufacturers of the listed drug classes and other applicants may submit electronic comments or objections, or file a written request for a hearing, on or before March 28, 2025, via https://www.regulations.gov or by the addresses listed in the notice. Comments will produce a Comment…
- Approval Limits: No Finished Dosage Imports for Sale: cost, medium. The notice states that any registration approval will only be granted if the applicant's business activity is consistent with 21 U.S.C. 952(a)(2), and the authorization will not permit importation of Food and Drug Administration‑approved or non‑approved finished dosage forms for commercial sale.

## Related documents

- [2026-11526](https://policyrisk.com/federal-register/2026-11526): Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 201…, 2026-06-09
- [2026-10128](https://policyrisk.com/federal-register/2026-10128): Revision of Applications for Manufacturing and Procurement Quotas, 2026-05-20
- [2025-05007](https://policyrisk.com/federal-register/2025-05007): Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients, 2025-03-24
- [2025-02793](https://policyrisk.com/federal-register/2025-02793): Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients, 2025-02-19
- [2026-22843](https://policyrisk.com/federal-register/2026-22843): Proposed Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ep…, 2026-11-10
- [2026-22842](https://policyrisk.com/federal-register/2026-22842): Adjustment to the 2026 Aggregate Production Quota for d,l-Amphetamine, d-Amphetamine (for Sale), Hydromorphone and Methylphenidate (for Sal…, 2026-11-10

## Sources
- [2025-03060 on federalregister.gov](https://www.federalregister.gov/documents/2025/02/26/2025-03060/importer-of-controlled-substances-application-sharp-clinical-services-llc)
- [2025-03060 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2025-02-26/pdf/2025-03060.pdf)

## Related
- [Previous: 2025-03025, Self-Regulatory Organizations; Cboe BZX Exchange, Inc.; Notice of Filing of a P…](https://policyrisk.com/federal-register/2025-03025)
- [Next: 2025-03061, Importer of Controlled Substances Application: Catalent Pharma Solutions, LLC](https://policyrisk.com/federal-register/2025-03061)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2025-03060 (as of 2026-09-25).
